Pharmacoeconomics applied to chronic hepatitis C
Braz. j. infect. dis
;
10(1): 51-54, Feb. 2006. tab, graf
Artigo
em Inglês
| LILACS
| ID: lil-428716
RESUMO
Life expectancy has increased over the last century as it had never been before. This is the result of a combination of many favorable variables such as level of education, improved socio-economic environment and development of medicine. However, new improvements demand heavy investment. Thus, the incorporation of medical technology became a health and economic issue. The pharmacoeconomic knowledge field is being developed to help in the analysis of medical costs and patient needs. The applies to hepatitic C, a common and chronic worldwide disease. In this article, the authors describe the rational behind this type of health economic analysis and review a hepatitis C model. Overall, in a non-Brazilian scenario, it was demonstrated that peginterferon alfa-2a (40KD) is cost effective in the treatment of HCV disease.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Antivirais
/
Ribavirina
/
Interferon-alfa
/
Hepatite C Crônica
Tipo de estudo:
Avaliação Econômica em Saúde
/
Estudo prognóstico
Limite:
Humanos
Idioma:
Inglês
Revista:
Braz. j. infect. dis
Assunto da revista:
Doenças Transmissíveis
Ano de publicação:
2006
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Roche Brazil/BR
/
State University of Rio de Janeiro/BR
/
University of São Paulo/BR
Similares
MEDLINE
...
LILACS
LIS